Ozanimod
CAS 1306760-87-1 5 FDA-DMF suppliersSmall Molecule
Overview
Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator, used for the treatment of relapsing forms of multiple sclerosis and ulcerative colitis. By modulating S1P receptors, it reduces lymphocyte migration into the central nervous system and other tissues.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Ozanimod expires 29 Sept 2038 and exclusivity 29 Aug 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Multiple SclerosisUlcerative Colitis
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.